Efficacy of 12-month therapy with SC MTX in patients with recently emerged RA with different BMI
| Group (n) | 1 (20) | 2 (17) | 3 (10) |
|---|---|---|---|
| 3 months of treatment | |||
| AD, mg/m2, M±σ (p1–2=0.03; p1–3=0.0009; p2–3=0.07) | 12.7±1.9 | 11.3±1.6 | 10.3±1.1 |
| Remission according to ACR/EULAR 2011 | 4 (20%) | 1 (6%) | 0 |
| 6 months of treatment | |||
| DAS28CRP, M±σ (p1–2=0.05; p1–3=0.03; p2–3=0.27) | 2.1±0.96 | 2.6±0.7 | 3±0.8 |
| SDAI, median [25; 75] (p1–2=0.3; p1–3=0.03; p2–3=0.2) | 4.3 [2.2; 7.5] | 5.5 [3.0; 8.6] | 10.0 [7.1; 13.6] |
| AD, mg/m2, M±σ (p1–2=0.002; p1–3=0.0001; p2–3=0.006) | 13.3 [12.5; 14.3] | 11.5 [10.5; 12.0] | 9.4 [8.3; 10.4] |
| Remission according to ACR/EULAR 2011 (p1–2=0.2; p1–3=0.3; p2–3=0.6) | 6 (30%) | 4 (24%) | 1 (10%) |
| 12 months of treatment | |||
| DAS28ESR. M±σ (p1–2=0.03; p1–3=0.2; p2–3=0.27) | 2.0±0.7 | 2.9±0.9 | 2.4±0.7 |
| DAS28CRP, M±σ (p1–2=0.02; p1–3=0.2; p2–3=0.6) | 1.7±0.6 | 2.4±0.8 | 2.3±0.6 |
| SDAI, median [25; 75] (p1–2=0.03; p1–3=0.01; p2–3=0.8) | 1.2 [0.5; 4.0] | 3.3 [2.3; 9.9] | 4.3 [2.6; 7.0] |
| CRP, mg/l, median [25; 75] (p1–2=0.01; p1–3=0.007; p2–3=0.6) | 1.1 [0.2; 3.1] | 3.7 [1.6; 7.9] | 4.0 [2.2; 9.4] |
| AD, mg/m2, M±σ (p1–2=0.08; p1–3=0.001; p2–3=0.09) | 13.1±2.2 | 11.5±2.0 | 10.2±1.7 |
| Necessity of bDMARDs usage, % (p1–2=0.02; p1–3=0.002) | 23% | 60% | 60% |
| Remission according to ACR/EULAR 2011 (p1–2=0.1; p1–2=0.07; p1–2=1) | 12 (60%) | 5 (30%) | 3 (30%) |